Apurano Pharmaceuticals GmbH

5 trials Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

0 Recruiting

4 Completed trials

2 Countries active

22 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 4 Phase II: 1

Oversight events:

8 temporary halts 4 corrective measures across 4 trials

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

All trials

5 total

Clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder Pending

2024-510873-11-00 Phase II 1 country ADEZUNAP
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy Ended

2022-500897-32-00 Phase III 2 countries ADEZUNAP
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy Ended

2022-500898-13-00 Phase III 2 countries ADEZUNAP
Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis Ended

2022-500899-66-00 Phase III 2 countries ADEZUNAP
Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain Ended

2022-502151-54-00 Phase III 2 countries ADEZUNAP

Showing 1–5 of 5 trials

← All sponsors A–Z